2021
Implementation of Inpatient Palliative Care Consultation Triggers and Its Impact on Healthcare Use in Patients with Relapsed/Refractory Acute Myeloid Leukemia
Xiang J, Prsic E, Adelson K, Prebet T. Implementation of Inpatient Palliative Care Consultation Triggers and Its Impact on Healthcare Use in Patients with Relapsed/Refractory Acute Myeloid Leukemia. Blood 2021, 138: 3018. DOI: 10.1182/blood-2021-149300.Peer-Reviewed Original ResearchRefractory acute myeloid leukemiaAcute myeloid leukemiaPost-intervention groupLength of stayAdvanced acute myeloid leukemiaPalliative care consultHigh symptom burdenLines of therapyCare consultEnd of lifeDay of deathSame admissionCare escalationSymptom burdenHospice enrollmentHealthcare utilizationSymptom managementPrimary teamMyeloid leukemiaEastern Cooperative Oncology Group performance statusRelapsed/Refractory Acute Myeloid LeukemiaHigh-risk hematology patientsAdvance care planning documentationPalliative care remainsPalliative care useImpact of an automatic palliative care consultation trigger on healthcare use in patients with relapsed/refractory acute myeloid leukemia.
Xiang J, Prsic E, Adelson K, Ozyck R, Prebet T. Impact of an automatic palliative care consultation trigger on healthcare use in patients with relapsed/refractory acute myeloid leukemia. Journal Of Clinical Oncology 2021, 39: 224-224. DOI: 10.1200/jco.2020.39.28_suppl.224.Peer-Reviewed Original ResearchRefractory acute myeloid leukemiaAcute myeloid leukemiaPost-intervention groupLength of stayPalliative care consultLines of therapyAdvance care planningCare consultHealthcare usePrimary teamMyeloid leukemiaCare planningAdvanced acute myeloid leukemiaPalliative care remainsPalliative care useSmilow Cancer HospitalECOG performance statusHigh-risk patientsHigher healthcare utilizationProspective cohort studyTertiary academic centerTimes/weekAML risk stratificationCriteria 1Fisher's t-testPatterns of treatment with everolimus exemestane in hormone receptor-positive HER2-negative metastatic breast cancer in the era of targeted therapy
Rozenblit M, Mun S, Soulos P, Adelson K, Pusztai L, Mougalian S. Patterns of treatment with everolimus exemestane in hormone receptor-positive HER2-negative metastatic breast cancer in the era of targeted therapy. Breast Cancer Research 2021, 23: 14. PMID: 33514405, PMCID: PMC7844919, DOI: 10.1186/s13058-021-01394-y.Peer-Reviewed Original ResearchConceptsPrior endocrine therapyEndocrine therapyMetastatic breast cancerEffective treatment optionTreatment optionsBreast cancerMedian treatmentMedian OSEE therapyHormone receptor-positive HER2-negative metastatic breast cancerMultivariable Cox proportional hazards regression analysisHER2-negative metastatic breast cancerPrior treatmentCox proportional hazards regression analysisFirst-line therapy initiationProportional hazards regression analysisPrior treatment optionsLines of therapyProportion of patientsKaplan-Meier methodHazards regression analysisPatterns of treatmentElectronic health record-derived dataClinical trial dataOS benefit
2017
Racial disparities in the use of programmed death-1 checkpoint inhibitors.
O'Connor J, Seidl-Rathkopf K, Torres A, You P, Nussbaum N, Fessele K, Darius K, Adelson K, Yin E, Presley C, Chiang A, Ross J, Abernethy A, Gross C. Racial disparities in the use of programmed death-1 checkpoint inhibitors. Journal Of Clinical Oncology 2017, 35: 3068-3068. DOI: 10.1200/jco.2017.35.15_suppl.3068.Peer-Reviewed Original ResearchDeath-1 checkpoint inhibitorsElectronic health record databaseLines of therapySystemic therapyCheckpoint inhibitorsCancer clinicRacial disparitiesAdvanced non-small cell lung cancerNon-small cell lung cancerMetastatic renal cell carcinomaAnti-PD1 treatmentCell lung cancerRenal cell carcinomaHealth record databaseSignificant racial disparitiesNew cancer drugsSquamous histologyStudy drugReal-world practiceAdvanced melanomaTherapy linesWhite patientsMale sexCell carcinomaLung cancer